Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress.

Front Immunol · 2023 · PMC9911663 · PMID 36776840

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an interesting trendno p-value reported

On the contrary, in the MERIT trial, testing nivolumab in a similar pretreated population, an interesting trend (not statistically significant) in favor of PD-L1 positivity compared to PD-L1 negativity was reported in terms of ORR (40% (95% CI 21.9–61.3) vs 8% (95% CI 1.5–35.4); PFS (7.2 months vs 2.9 months; p=0.4490), and OS (17.3 months vs 11.6 months; p=0.2021) ( 15 , 89 ).

also in 1,783 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.